An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie diagnoza raka prostaty
- •Nawrót choroby po radykalnym leczeniu (operacja prostaty lub radioterapia)
- •1-5 przerzutów widocznych w badaniu obrazowym PSMA PET/CT
- •Co najmniej jeden przerzut poza lokal pierwotnego guza
- •Dodatnia próba PSMA w obrazach diagnostycznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- August 3, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (144)
Highlands Oncology Group
Fayetteville, United States
VA Greater LA Healthcare System
Los Angeles, United States
VA Palo Alto Health Care System
Palo Alto, United States
Stanford University
Palo Alto, United States
UCSF
San Francisco, United States
Rocky Mountain Cancer Centers
Denver, United States
Cancer Specialists of North Florida
Jacksonville, United States
Woodlands Medical Specialists
Pensacola, United States
Piedmont Healthcare
Atlanta, United States
University of Chicago
Chicago, United States
The Cancer Institute of Alexian Brothers
Elk Grove, United States
Unity Point Clinic
Des Moines, United States
University of Kansas Hospital
Kansas City, United States
Mary Bird Perkins Cancer Center
Baton Rouge, United States
East Jefferson Hospital
Metairie, United States
University of Maryland Medical Ctr
Baltimore, United States
Johns Hopkins Kimmel Com Cancer Ctr
Baltimore, United States
Dana Farber Cancer Institute
Boston, United States
Beth Israel Deaconess Med Ctr
Boston, United States
BAMF Health
Grand Rapids, United States
Profound Research LLC
Royal Oak, United States
William Beaumont Hospital
Royal Oak, United States
Mayo Clinic Rochester
Rochester, United States
St Louis University
St Louis, United States
VA St Louis Health Care System
St Louis, United States
Wash U School of Medicine
St Louis, United States
The Urology Center PC DBA UroHealth Partners
Omaha, United States
Memorial Sloan Kettering Cancer Ctr
New York, United States
Associated Med Professionals of NY
Syracuse, United States
Montefiore Hospital
The Bronx, United States
East Carolina University
Greenville, United States
Dayton Physicians
Kettering, United States
Oregon Urology Institute
Springfield, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Vanderbilt University Medical Center
Nashville, United States
Univ of Texas Southwest Med Center
Dallas, United States
Rio Grande Urology
El Paso, United States
Virginia Oncology Associates
Norfolk, United States
Blue Ridge Cancer Center
Wytheville, United States
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Darlinghurst, Australia
Novartis Investigative Site
Herston, Australia
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
Malvern, Australia
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Aalst, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Calgary, Canada
Novartis Investigative Site
Halifax, Canada
Novartis Investigative Site
London, Canada
Novartis Investigative Site
Ottawa, Canada
Novartis Investigative Site
Toronto, Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Québec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Bogota, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Ostrava, Czechia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Saint-Cloud, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Munich, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Rostock, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Thessaloniki, Greece
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Beersheba, Israel
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Jerusalem, Israel
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Brescia, Italy
Novartis Investigative Site
Cona, Italy
Novartis Investigative Site
Genova, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Rozzano, Italy
Novartis Investigative Site
Pisa, Italy
Novartis Investigative Site
Roma, Italy
Novartis Investigative Site
Negrar, Italy
Novartis Investigative Site
Kashiwa, Japan
Novartis Investigative Site
Sapporo, Japan
Novartis Investigative Site
Kobe, Japan
Novartis Investigative Site
Yokohama, Japan
Novartis Investigative Site
Chuo Ku, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Fukushima, Japan
Novartis Investigative Site
Ishikawa, Japan
Novartis Investigative Site
Kyoto, Japan
Novartis Investigative Site
Petaling Jaya, Malaysia
Novartis Investigative Site
Kuala Lumpur, Malaysia
Novartis Investigative Site
Mexico City, Mexico
Novartis Investigative Site
Huxquilucan, Mexico
Novartis Investigative Site
Amsterdam, Netherlands
VA Caribbean Healthcare System
San Juan, Puerto Rico
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Bratislava, Slovakia
Novartis Investigative Site
Košice, Slovakia
Novartis Investigative Site
Nitra, Slovakia
Novartis Investigative Site
Trenčín, Slovakia
Novartis Investigative Site
Granada, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
El Palmar, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Seville, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Geneva, Switzerland
Novartis Investigative Site
Lucerne, Switzerland
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taoyuan, Taiwan
Novartis Investigative Site
Bristol, United Kingdom
Novartis Investigative Site
Guildford, United Kingdom
Novartis Investigative Site
Coventry, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.